Gathering patient perspectives in pharma is a priority for the pharma industry, and for good reason – there’s plenty of data to suggest that centering patients and their experiences is much more than just noble ideals. In one study comparing trials with significant patient-centered elements to traditional trials, researchers found that 87% of the patient-centered trials had positive results, much higher than 68% for the traditional trials. And companies that take more patient-centric approaches to trial design and execution have moved the needle on reducing average trial enrollment time and shortening the timeline from first patient dose to product launch.
Clearly, pharmaceutical teams can add significant value by making patient engagement more frequent and more meaningful. Let’s examine how teams can add this strategic capability and break down a few barriers to better patient engagement.
Building a more patient-centric approach
Technological advancements ushered in telehealth, remote monitoring, and wearable devices that help HCPs and patients better understand disease states and therapy adherence. But pharma organizations can do their part, too – starting as soon as the earliest stages of drug development and continuing throughout clinical studies, launch, and post-market monitoring.
Deloitte reports that to build a more patient-centric organization, life science companies should:
- Harness digital and data analytics opportunities to engage patients
- Collect data on patient outcomes and their unmet needs
- Form deeper collaborations within the industry, including with advocacy groups, clinicians, and health plans
To increase the likelihood of patient engagement success. Galapagos used the Within3 insights management platform to support its Patient Engagement Council (PEC), which brings together representatives from 11 patient organizations and independent patient experts.
The ability to engage the PEC conveniently and flexibly supports Galapagos in achieving its goal of systematic patient engagement across the medicine lifecycle. “We believe using the platform contributed to establishing and maintaining a successful collaboration with all the external advisors, whose input and recommendations are invaluable to Galapagos,” said Marina Sardone, Patient Advocacy Lead, Galapagos.
Barriers to better patient engagement
Your organization may believe it is patient-centric by nature – after all, you develop and launch therapies designed to treat patients. But as the Deloitte report points out, the patient perspective is typically filtered through the lens of physicians or regulators. Designing trials and creating educational materials with patients in mind isn’t really the same thing as bringing the patient into the process from the beginning.
“We work really hard to incorporate the patient’s voice into everything we do. But often, the patient’s voice is filtered through a healthcare provider or another stakeholder. So it was extremely important to be able to hear directly from patients, without someone putting words in their mouth or changing the tone, as to what their experiences were.” – Within3 medical affairs client
In a conversation hosted by MAPS and Within3, medical affairs leaders discussed roadblocks to improving patient engagement, including questions about who owns the function within the organization. Other issues, like patient distrust of pharma or the medical establishment, access barriers like language differences, and the dearth of information on rare diseases further compound the challenge of engaging patients across different channels. And while technology such as AI offers intriguing possibilities for bridging language and education gaps, many organizations remain unsure about how to compliantly use AI in patient-facing settings. Related: get a detailed breakdown of the discussion, including suggestions for next steps, in our exclusive summary.
Preparing for patient-centricity
Good patient engagement strategies enable true patient focus across pharma organizations. Clinical teams can design patient-focused trials with the right virtual engagement tactics and tools, and the patient story can enable medical affairs teams to help healthcare professionals understand more about the patient experience. Commercial teams can solicit candid patient input to craft messages that better understand a particular diagnosis’s medical and emotional implications.
How can pharma teams build this capability? And what are the keys to successful patient engagement?
The answer begins with understanding what your team is trying to achieve. In other words, begin with the destination and plan accordingly. When it comes to designing a successful patient engagement approach, key best practices include:
- Adequately preparing patients for what to expect
- Using a systematic approach to question selection
- Providing multiple channels and opportunities for input
- Establishing a supportive community setting
Watch the video to hear what our global client success team has learned from helping clients lead patient engagement sessions. You can also scroll down to read the transcript.
Ready to put patient centricity into action? Get our five best practices for creating effective virtual patient engagements.
Video transcript: Prioritizing the patient voice
Kristin Kaderli:
Using the platform really just is a playing field leveler, I think. It allows them to reach people at a depth and a frequency that they might not have been able to reach them before, you know, when they’re trying to engage them in person.
Sylke Anderson:
The patients were just extremely enthusiastic. They had started with a face-to-face or a Zoom meeting and they were actually really moved by the company’s desire to engage them in this way and to really understand what they were going through, not only themselves but with their family members.
Christine D’Elia:
This opens the door to a very wide variety of patients and even caregivers that can, you know, share their input, share their journeys, and share their stories.
Ken Hersche:
So they actually open up quite a bit about themselves and from that our client actually learn new things about the patients and how maybe they deal with their disease over time. Just some things that only a patient would know.
Kristin Kaderli:
The longitudinal thing I saw with this is that they took the experience from these patient engagements and extended it to mid-level physicians, which are often the people that see these symptoms first in the community. And then also obviously with KOLs and other community physicians.
Sylke Anderson:
The insights and the input the client received were just extremely valuable, highly in depth.
Christine D’Elia:
The Within3 platform used in this way gave patients a voice in a way that’s accessible and convenient for them.
Ken Hersche:
Some of these particular patients in this therapeutic area, for example, may have difficulty with being mobile or having long extended discussions in one room or area. So this need was really met through our asynchronous offering cuz it really allowed the patients to discuss at a place in time of the convenience. With
Sylke Anderson:
This platform, they’re able to kind of come and go at their convenience, kind of discuss their experiences with other patients who were going through, through similar things. And always ensure that they had an equal share of voice, no matter how much time they were able to spend on the platform. And when they came and went.
Kristin Kaderli:
I think a lot of times that psychological barrier, like, are my patients willing to do this? They are, they will be and they wanna be heard, especially when they have a condition that isn’t widely known about or recognized.
